Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer

Prostate

Volumn 62, Issue 2, 2005, Pages 140-147

  Hara, Noboru ^a,b   Okuizumi, Mina ^a   Koike, Hiroshi ^a   Kawaguchi, Makoto ^a   Bilim, Vladimir ^b  

^a Niigata Rousai Hospital   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Characterization; Localization; Visualization

Indexed keywords

GADOLINIUM PENTETATE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EARLY CANCER; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY;

AGED; BIOPSY; EARLY DIAGNOSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 11844287000     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20124     Document Type: Article

References (44)

1. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-1290.
2. Pansadoro V, Emiliozzi P, Defidio L, Scarpone P, Sabatini G, Brisciani A, Lauretti S. Prostate-specific antigen and prostatitis in men under fifty. Eur Urol 1996;30:24-27.
3. Ornstein DK, Smith DS, Humphrey PA, Catalona WJ. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J Urol 1998;159:1234-1237.
4. Purohit RS, Shinohara K, Meng MV, Carroll PR. Imaging clinically localized prostate cancer. Urol Clin North Am 2003;30:279-293.
5. Ikonen S, Kivisaari L, Tervahartiala P, Vehmas T, Taari K, Rannikko S. Prostatic MR imaging. Accuracy in differentiating cancer from other prostatic disorders. Acta Radiol 2001;42:348-354.
6. Comet-Batlle J, Vilanova-Busquets JC, Saladie-Roig JM, Gelabert-Mas A, Barcelo-Vidal C. The value of endorectal MRI in the early diagnosis of prostate cancer. Eur Urol 2003;44:201-208.
7. Renshaw AA. Sub-classification of renal cell neoplasms: An update for the practicing patholosist. Histopathol 2002;41:283-300.
8. Kwak HS, Lee JM, Kim CS. Preoperative detection of hepatocellular carcinoma: Comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol 2004;14:447-457.
9. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-75.
10. Fink KG, Hutarew G, Pytel A, Esterbauer B, Jungwirth A, Dietze O, Schmeller NT. One 10-core prostate biopsy is superior to two sets of sextant prostate biopsies. BJU Int 2003;92:385-388.
11. Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncoso P, Babaian RJ. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology 2002;60:836-840.
12. Fink KG, Hutarew G, Lumper W, Jungwirth A, Dietze O, Schmeller NT. Prostate cancer detection with two sets of ten-core compared with two sets of sextant biopsies. Urology 2001;58: 735-739.
13. Emiliozzi P, Scarpone P, DePaula F, Pizzo M, Federico G, Pansadoro A, Martini M, Pansadoro V. The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: A randomized study of 6 versus 12 core transperineal prostate biopsy. J Urol 2004;171:197-199.
14. Furuno T, Demura T, Kaneta T, Gotoda H, Muraoka S, Sato T, Nagamori S, Shinohara N, Koyanagi T. Difference of cancer core distribution between first and repeat biopsy: In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate 2004;58:76-81.
15. Kawata N, Miller GJ, Crawford ED, Torkko KC, Stewart JS, Lucia MS, Miller HL, Hirano D, Werahera PN. Laterally directed biopsies detect more clinically threatening prostate cancer: Computer simulated results. Prostate 2003;57:118-128.
16. Taylor JA III, Gancarczyk KJ, Fant GV, Mcleod DG. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology 2002;60:841-845.
17. Bott SR, Young MP, Kellett MJ, Parkinson MC; Contributors to the UCL Hospitals' Trust Radical Prostatectomy Database. Anterior prostate cancer: Is it more difficult to diagnose? BJU Int 2002;89:886-889.
18. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies. J Urol 1996;156:1059-1063.
19. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-294.
20. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994;152:1732-1736.
21. Renshaw AA, Schultz D, Cote K, Loffredo M, Ziemba DE, D'Amico AV. Accurate Gleason grading of prostatic adenocarcinoma in prostate needle biopsies by general pathologists. Arch Pathol Lab Med 2003;127:1007-1008.
22. Smith EB, Frierson HF Jr., Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: Is there evidence for systematic upgrading? Cancer 2002;94:2282-2287.
23. Allsbrook WC Jr., Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: General pathologist. Hum Pathol 2001;32: 81-88.
24. Moreno JG, O'Hara SM, Long JP, Veltri RW, Ning X, Alexander AA, Gomella LG. Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR. Urology 1997;49:515-520.
25. Paik HC, Lee DY, Lee HK, Kim SJ, Lee KB. Chest wall implantation of carcinoma after fine needle aspiration biopsy. Yonsei Med J 1994;35:349-354.
26. Voravud N, Shin DM, Dekmezian RH, Dimery I, Lee JS, Hong WK. Implantation metastasis of carcinoma after percutaneous fine-needle aspiration biopsy. Chest 1992;102:313-315.
27. Hara N, Kasahara T, Kawasaki T, Bilim V, Tomita Y, Obara K, Takahashi K. Frequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsy. Br J Cancer 2001;85:557-562.
28. Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, de la Rosette JJ, Blickman JG, Barentsz JO. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003;229:248-254.
29. Coakley FV, Qayyum A, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 2003;170:S69-S76.
30. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-848.
31. Blijenberg BG, Storm BN, Kruger AE, Schroder FH. On the standardization of total prostate-specific antigen: An exercise with two reference preparations. Clin Chem Lab Med 1999;37: 545-552.
32. Kano S, Ishibashi M, Itoh Y, PSA ad hoc Committee of Japanese Urological Association. The present status of standardization in serum total PSA measurement-A result of "Survey 2000" conducted by PSA Ad Hoc Committee of Japanese Urological Association. Rinsho Byori 2001;49:967-973.
33. Hara N, Koike H, Ogino S, Okuizumi M, Kawaguchi M. The application of serum PSA to identify acute bacterial prostatitis in patients with fever of unknown origin or symptoms of acute pyelonephritis. Prostate (in press).
34. Bo M, Ventura M, Marinello R, Capello S, Casetta G, Fabris F. Relationship between prostatic specific antigen (PSA) and volume of the prostate in the benign prostatic hyperplasia in the elderly. Crit Rev Oncol Hematol 2003;47:207-211.
35. Preston DM, Levin LI, Jacobson DJ, Jacobsen SJ, Rubertone M, Holmes E, Murphy GP, Moul JW. Prostate-specific antigen levels in young white and black men 20 to 45 years old. Urology 2000;56:812-816.
36. Padhani AR, Gapinski CJ, Macvicar DA, Parker GJ, Suckling J, Revell PB, Leach MO, Dearnaley DP, Husband JE. Dynamic contrast enhanced MRI of prostate cancer: Correlation with morphology and tumour stage, histological grade, and PSA. Clin Radio 2000;55:99-109.
37. Outwater EK, Petersen RO, Siegelman ES, Gomella LG, Chernesky CE, Mitchell DG. Prostate carcinoma: Assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 1994;193:333-339.
38. Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol 2001;166:845-850.
39. Furuno T, Demura T, Kaneta T, Gotoda H, Muraoka S, Sato T, Nagamori S, Shinohara N, Koyanagi T. Difference of cancer core distribution between first and repeat biopsy: In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate 2004;58:76-81.
40. Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P, Rannikko S. Magnetic resonance imaging of prostatic cancer: Does detection vary between high and low gleason score tumors? Prostate 2000;43:43-48.
41. Karam JA, Mason RP, Koeneman KS, Antich PP, Benaim EA, Hsieh JT. Molecular imaging in prostate cancer. J Cell Biochem 2003;90:473-483.
42. Ito H, Kamoi K, Yokoyama K, Yamada K, Nishimura T. Visualization of prostate cancer using dynamic contrast-enhanced MRI: Comparison with transrectal power Doppler ultrasound. Br J Radiol 2003;76:617-624.
43. Rouviere O, Raudrant A, Ecochard R, Colin-Pangaud C, Pasquiou C, Bouvier R, Marechal JM, Lyonnet D. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 2003;13:931-942.
44. Hasumi M, Suzuki K, Taketomi A, Matsui H, Yamamoto T, Ito K, Kurokawa K, Aoki J, Endo K, Yamanaka H. The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Anticancer Res 2003;23:4223-4227.